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Background: Feline calicivirus (FCV) is an important pathogen of cats for which vaccination is regularly
practised. Long-term use of established vaccine antigens raises the theoretical possibility that field
viruses could become resistant. This study aimed to assess the current ability of the FCV-F9 vaccine strain
to neutralise a randomly collected contemporary panel of FCV field strains collected prospectively in six
European countries.
Methods: Veterinary practices (64) were randomly selected from six countries (UK, Sweden, Netherlands,
Germany, France and Italy). Oropharyngeal swabs were requested from 30 (UK) and 40 (other countries)
cats attending each practice. Presence of FCV was determined by virus isolation, and risk factors for FCV
shedding assessed by multivariable logistic regression. Phylogenetic analyses were used to describe the
FCV population structure. In vitro virus neutralisation assays were performed to evaluate FCV-F9 cross-
reactivity using plasma from four vaccinated cats.
Results: The overall prevalence of FCV was 9.2%. Risk factors positively associated with FCV shedding
included multi-cat households, chronic gingivostomatitis, younger age, not being neutered, as well as
residing in certain countries. Phylogenetic analysis showed extensive variability and no countrywide
clusters. Despite being first isolated in the 1950s, FCV-F9 clustered with contemporary field isolates.
Plasma raised to FCV-F9 neutralized 97% of tested isolates (titres 1:4 to 1:5792), with 26.5%, 35.7% and
50% of isolates being neutralized by 5, 10 and 20 antibody units respectively.
Conclusions: This study represents the largest prospective analysis of FCV diversity and antigenic cross-
reactivity at a European level. The scale and random nature of sampling used gives confidence that the
FCV isolates used are broadly representative of FCVs that cats are exposed to in these countries. The
in vitro neutralisation results suggest that antibodies raised to FCV-F9 remain broadly cross-reactive to
contemporary FCV isolates across the European countries sampled.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction This diverse genogroup is mirrored by a single diverse serotype;Feline calicivirus (FCV) is a common pathogen of cats causing
oral and upper respiratory tract disease (URTD) [1]. It has a
single-stranded, positive-sense RNA genome [2], the plasticity of
which is important for antigenic evolution, viral persistence [3,4]
recombination [5,6], and the sporadic outbreaks of highly virulent
FCV strains causing severe disease [1,7,8]. Despite high levels of
variability, FCV strains are generally considered to comprise one
diverse genogroup with a radial phylogeny and little evidence for
sub-species clustering [9–14].although individual strains are distinguishable antigenically, they
generally show some cross-reactivity [15–18], allowing the devel-
opment of several FCV vaccines based on different antigens [1].
Whilst vaccines reduce clinical signs, none are licensed to reduce
virus shedding post-challenge and FCV infection remains highly
prevalent in both vaccinated and unvaccinated populations [1].
Most live vaccines include FCV-F9 [19,20], whereas inactivated
vaccines commonly include strains FCV-255, or a combination of
FCV-431 and FCV-G1 [18,21,22]. These vaccine antigens are chosen
based on their ability to induce broadly cross-reactive antisera
against contemporary isolates circulating at the time of vaccine
development [17,20,22]. The widespread use of such vaccines
together with the high adaptability of FCV raises the theoreticalnd vac-
2 M.M. Afonso et al. / Vaccine xxx (2017) xxx–xxxpossibility that vaccine resistant strains may evolve over time.
Whilst some studies have supported this hypothesis [23–25],
others have not [26].
Here we describe the antigenic and genetic relationships
between FCV-F9 and a representative panel of currently circulating
FCV strains, obtained from randomly selected veterinary practices
across six European countries.2. Materials and methods
2.1. Ethical statement
Ethical approval was from the Veterinary Research Ethics Com-
mittee, University of Liverpool. Informed consent was obtained
from participating owners.
2.2. Recruitment
Samples were collected between October 2013 and May 2014
from cats attending veterinary practices in the UK, France, Italy,
Netherlands, Sweden and Germany.
In the UK, three Unitary Authorities (UAs) were randomly cho-
sen from each of the nine regions of England, as well as from
Wales, Scotland and Northern Ireland. Geographically remote
islands were also selected (Western Isles, Orkney, Shetland, Angle-
sey, Isle of Wight, Scilly Isles, Isle of Man, Channel Islands) based on
convenience. From each of these 44 regions, a small animal prac-
tice was randomly selected from the Royal College of Veterinary
Surgeons database. The remaining five countries were chosen
based on convenience, divided into five regions based on official
divisions and/or local geography, and a single practice randomly
selected from each. If chosen practices declined to participate, a
further practice was randomly selected. This process was repeated
up to three times until a practice in each region agreed to take part.
2.3. Field isolates
There is much debate regarding the most appropriate FCV iso-
lates to use for assessment of in vitro neutralisation. Several studies
have used isolates obtained by convenience from diagnostic labo-
ratories to represent pathogenic viruses [23–25]; lack of random
sampling means such results may not be generalizable to the wider
population [24]. Here we sample sick and healthy cats randomly to
ensure our results are representative of the sampled population.
The occasional description of non-pathogenic FCV strains [27]
requires us to justify the inclusion of isolates from healthy animals.
In this regard, it should be noted that FCV isolates from healthy
cats can still be pathogenic: virulent FCV continues to be shed from
cats recovered from acute disease [27], and seropositive cats previ-
ously exposed to vaccine or field virus may shed virus in absence of
clinical signs when subsequently challenged with virulent virus
[19]. Indeed, experimental challenge has confirmed that FCV from
healthy cats can recreate typical disease [27].
In each practice, veterinary surgeons were asked to collect
oropharyngeal swabs from the next 30 (UK) or 40 (other countries)
cats presented at their surgery regardless of reason for presenta-
tion (diseased or healthy). Random recruitment of practices and
random sampling of cats based on attendance at these practices
were used to ensure results could be generalised to the sampled
population, and is in contrast to an earlier study by the authors
where sampling was by convenience [10].
Swabs were collected into virus transport medium, stored at
20 C before shipping to the laboratory. The veterinary surgeon
and owner were asked to complete a short questionnaire capturing
demographic data, vaccination history and information about cur-Please cite this article in press as: Afonso MM et al. A multi-national European
cine cross-reactivity. Vaccine (2017), http://dx.doi.org/10.1016/j.vaccine.2017.0rent respiratory disease, mouth ulcers and chronic gingivostomati-
tis (CGS).
2.4. Viral isolation (VI)
Feline calicivirus was isolated using standard techniques [28]
based on presence of typical cytopathic effect (CPE). Samples were
only considered negative after two passages [29].
2.5. RNA extraction and reverse transcription-PCR
Viral RNA was extracted from positive cell cultures (second pas-
sage or less) (Viral RNA mini-kit; Qiagen). One negative control
(mock infected cells) was included for each three samples. Reverse
transcription was performed using 200 ng random hexamers
(Superscript III, Life Technologies). A 529-nucleotide region of the
capsid gene, equivalent to residues 6406-6934 of FCV-F9 (GenBank
M86379) and incorporating immunodominant regions C and E
[3,30], was amplified according to manufacturer’s guidelines
(Reddy-Mix; Thermo scientific) and published protocols using 25p-
moles of each primer per 50 ml reaction [10]. In addition, 486-
nucleotides from the 30 end of the FCV polymerase gene were also
sequenced as previously described [10].
2.6. Nucleotide sequencing and phylogenetic analysis
Amplicons were purified (QIAquick; Qiagen), quantified (Nan-
odrop; Genequant) and sequenced (Source Bioscience; Notting-
ham). Forward and reverse sequences were aligned (ChromasPro;
Technelysium), and pairwise p-distances and neighbour-joining
trees (1000 bootstrap replicates) calculated using MEGA7. A
threshold of 20% uncorrected nucleotide distance was used to
define distinct strains [31,32].
2.7. Epidemiological analysis
Prevalence estimates with 95% confidence intervals were deter-
mined (Epitools; AusVet) based on results of VI. Data from ques-
tionnaires were used to examine risk factors and associations
with FCV carriage. Univariable and multivariable multilevel logistic
regression allowing for clustering within practice was conducted
using MLwiN (v2.1, University of Bristol). Potential risk factors
included country, cat’s age, gender, breed, lifestyle, vaccination sta-
tus, vaccine strain, neutering status, presence of mouth ulcers,
URTD signs, CGS and number of cats in the household. Variables
with P–values <0.25 in initial univariable analysis were considered
in the multivariable model retaining variables with Wald P-values
<0.05.
2.8. Isolates and plasma for viral neutralisation (VN) testing
Isolates for VN testing were randomly selected with stratifica-
tion, approximately half were from the UK, the remainder from
other participating countries. There is no approved standard for
producing immune reagents for FCV neutralisation studies. Con-
ventional FCV vaccination induces insufficient neutralisation titres
[33], such that previous studies have used infection with vaccine
viruses to produce test sera [23–26]. This will likely impact on both
the quantity and range of any measured immune response com-
pared to vaccination, especially when the tested vaccines often
contain inactivated antigens. The plasma used in this study was
collected from animals used in a standard vaccine safety study
conducted by the funders. Four specific pathogen free cats were
vaccinated subcutaneously with 10 commercial doses of Nobivac
TricatTrio (FCV-F9 live-attenuated vaccine) at 8–9 weeks of age,
and again four weeks later. Blood samples were taken three weekscross-sectional study of feline calicivirus epidemiology, diversity and vac-
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induce a quantitatively higher response than routine vaccination,
the antigenic targets for the response should be broadly similar
to those of routine vaccination. The plasma from all four cats was
used as a pool for all tested isolates, and also separately for 10 ran-
domly selected isolates.2.9. Viral neutralisation assays
Virus neutralisation tests were performed using a constant
virus, varying plasma method. Briefly, duplicate, serial twofold
dilutions of plasma were incubated with 32–320 TCID50 [34] of
virus at 37 C for 1 h before addition to FEA cells which had been
plated 24hours previously at approximately 1  104 cells/well of
a 96 well plate. Plates were observed for CPE at 48 h and 120 h.
Antibody titres were expressed as 50% end points [35]. An internal
FCV-F9 homologous control was included in each experiment. AsFig. 1. Map showing the 64 recruited veterinary practices. Circles in red are the 50 practic
that did not send back samples during the study. (For interpretation of the references to
Please cite this article in press as: Afonso MM et al. A multi-national European
cine cross-reactivity. Vaccine (2017), http://dx.doi.org/10.1016/j.vaccine.2017.0homologous antibody titres can vary between experiments,
between serum from different cats and depending on the method
of challenge, antibody units (AU) for each isolate were calculated
using the titre of this internal control. One antibody unit (AU) is
the highest plasma dilution neutralizing 100TCID50 of homologous
virus in 50% of cultures [15]. AUs were also calculated using the
mean FCV-F9 titre of all experiments [26], excluding those in
which the internal homologous FCV-F9 titre was >2-fold either side
of the mean FCV-F9 titre for all experiments [33].3. Results
3.1. Study sample
Fifty (27 UK, 23 mainland Europe) of the 64 recruited practices
(78.1%) returned samples (Fig. 1). Of the 2140 samples requested,
1521 (71%) were received.es that supplied samples during the study. Blue circles are the 14 recruited practices
colour in this figure legend, the reader is referred to the web version of this article.)
cross-sectional study of feline calicivirus epidemiology, diversity and vac-
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Table 1
Summary of samples, isolates and strains identified in each country.
Country UK France Netherlands Germany Sweden Italy
Samples (n) 686 187 99 175 205 149
FCV Positive n (%, CI) 58 (8.4%, 0.06–0.1) 11 (5.8%, 0.03–0.09) 16 (16.2%, 0.09–0.2) 25 (14.2%, 0.09–0.19) 17 (8.3%, 0.05–0.12) 8 (5.4%, 0.02–0.09)
FCV Capsid Sequence 56 11 16 19 17 10
Strains (n) 48 11 14 14 14 10
Table 2
Multilevel multivariable logistic regression analysis (allowing for clustering within practice) of factors associated with FCV isolation in 1502 vet visiting cats from UK and
mainland Europe. P-values below 0.05 considered significant.
Variable Odds ratio 95% CI lower 95% CI upper P-value
Country
France 0.29 0.11 0.75 0.01
The Netherlands Ref.
Italy 0.234 0.087 0.631 0.004
Germany 0.72 0.31 1.65 0.44
Sweden 0.599 0.253 1.419 0.24
UK 0.434 0.213 0.88 0.02
Neutered status
Yes Ref.
No 1.69 1.053 2.736 0.03
Chronic gingivo-stomatitis
Yes Ref.
No 0.12 0.06 0.23 <0.001
No. cats/household
1 Ref.
2–3 1.75 1.10 2.79 0.02
4–10 2.82 1.49 5.31 0.001
>11 0.74 0.08 6.97 0.79
Age (month) 0.99 0.99 0.99 0.01
Level 2 variance (standard error) 0.035 (0.106)
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A total of 140 of 1521 samples tested positive for FCV (9.2%, 95%
confidence interval (CI) 7.8, 10.8), ranging from 5.4% in Italy to
16.2% in the Netherlands (Table 1).3.3. Epidemiological analysis
Questionnaires were not received for 1.2% of samples and there-
fore analysis was performed using 1502 questionnaire-sample
matches. Nine of twelve predictor variables were significantly
associated with FCV isolation in univariable analysis (data not pre-
sented). Of these, five remained significant on multivariable analy-
sis (Table 2): Cats sampled in France, Italy and the UK were at a
lower risk of shedding FCV than those from the Netherlands. Entire
(non-neutered) cats were 1.7 times more likely to shed FCV than
neutered cats, regardless of gender. Cats in multi-cat households
were 1.7 (2–3 cats) and 2.8 (4–10 cats) times more likely to shed
FCV than cats living alone. Cats with CGS were 8.3 times more
likely to shed FCV than those without. Finally, each additional year
of a cat’s age reduced FCV shedding likelihood by 12%. Vaccination
was not significantly associated with risk of FCV infection in the
final model.3.4. Sequencing and phylogenetic analysis
A total of 128 partial capsid consensus sequences were obtained
from the 140 FCV isolates (Fig. 2; GenBank accession numbers
KX257491–KX257617). The unamplified isolates typical of such
experiments are presumed to be caused by primer mismatches
[10,11]. In total, 110 strains (pairwise genetic distance >20%) were
observed, ranging from 10 (Italy) to 48 (UK) (Table 1). Of thesePlease cite this article in press as: Afonso MM et al. A multi-national European
cine cross-reactivity. Vaccine (2017), http://dx.doi.org/10.1016/j.vaccine.2017.0strains, only 10 were represented by more than one isolate (boot-
strap values >80%; A to L on Fig. 2). The largest cluster included
FCV-F9-like isolates from the UK and Sweden (D in Fig. 2). All other
strains with more than one variant were restricted to individual
practices, with no evidence for widespread or international trans-
mission. Similar phylogenetic results were obtained for the poly-
merase gene (Supplemental File 1).
3.5. Viral neutralisation assays
The reproducibility of VN assays was assessed in two ways.
Firstly, 10 field isolates were randomly repeated giving an average
difference in neutralisation titres between repeats of 2.08, compa-
rable to previous studies [34]. In addition, the mean homologous
titre for the internal FCV-F9 control across 19 experiments was 1
in 1658 ± 345 standard error (data not presented).
Viral neutralisation was attempted in 121 of the 140 FCV iso-
lates. In total, 98 VN tests were successfully completed (48 UK, 6
Sweden, 9 France, 16 Germany, 10 the Netherlands and 9 Italy;
Supplemental File 2); the remaining 23 failed due to inability to
regrow in cell culture, titration failure, or bacterial contamination.
Of these 98 FCV isolates, 95 (97%) were neutralized at titres
ranging from 1:4 to 1:5792 (Fig. 3a; Supplemental File 2). Whilst
group sizes precluded statistical analysis, the pattern of neutralisa-
tion appeared to be broadly similar when isolates from different
clinical presentations were compared (Supplemental File 3). The
VN results based on different countries are shown in Fig. 3b. When
titres were standardised to homologous FCV-F9 titres derived
within individual experiments, 26.5%, 35.7% and 50% of isolates
were neutralized by 5, 10 and 20 AUs respectively. When using
the same method as described previously [33], using only those
experiments where the titre for the internal FCV-F9 control was
within 2-fold of mean FCV-F9 titre across all experiments, 0%,cross-sectional study of feline calicivirus epidemiology, diversity and vac-
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Fig. 2. Unrooted Neighbor-Joining tree of 128 FCV partial capsid consensus sequences obtained from the national study (including the sequence of FCV vaccine strain F9
[GenBank accession No. M86379]). The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are shown, only
bootstrap values >80% are indicated. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree
and relate to the distance bar. The evolutionary distances were computed using the Tamura-Nei method and represent the number of base substitutions per site. The rate
variation among sites was modelled with a gamma distribution (shape parameter = 1). Codon positions included were 1st + 2nd + 3rd + Noncoding. All ambiguous positions
were removed for each sequence pair. There were a total of 435 positions in the final dataset. The geographical origin of sequences is shown in different colours. Those strains
represented by more than a single sequence (<20% capsid divergence) are boxed, additionally labelled A–L, and the intra-strain capsid diversity indicated next to the box;
isolates in each box originate from the same country and veterinary practice with the exception of cluster D, where all sequences were collected in different practices and two
different countries. Circles at the tip of the branch indicate isolates used in viral neutralisation testing: empty circles represent isolates from animals with either chronic or
acute upper respiratory tract disease (URTD) and full circles represent isolates from animals either without URTD or no information in regards to clinical status. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
M.M. Afonso et al. / Vaccine xxx (2017) xxx–xxx 520% and 32% of 25 isolates were neutralized by 5, 10 and 20 AUs
respectively (Table 3).
In order to analyse the variability of plasma from the four cats,
viral neutralizations with single cat plasma were undertaken for 10
random field isolates and FCV-F9 (Supplemental File 4). The
plasma from each cat had demonstrable neutralizing ability to
each isolate. However, there was variation in the order of individ-
ual cat responses, with some cats’ plasma seemingly neutralising
some viruses particularly well, and others less well.Please cite this article in press as: Afonso MM et al. A multi-national European
cine cross-reactivity. Vaccine (2017), http://dx.doi.org/10.1016/j.vaccine.2017.04. Discussion
Widespread use of individual vaccines is associated with a the-
oretical risk for the emergence of vaccine resistance strains, partic-
ularly for RNA viruses. Here we have undertaken the first
multinational European study to assess the current in vitro cross
reactivity of FCV-F9, first isolated over 40 years ago, and still one
of the most frequently used vaccine antigens [17]. In order to max-
imise the generalizability of our findings to the European catcross-sectional study of feline calicivirus epidemiology, diversity and vac-
3.030
Fig. 3. Results of viral neutralisation testing. A: VN titre ranges (% of isolates) for the current study. B: Percentage of isolates neutralized by 20, 10 and 5AU per country.
Table 3
Percentage of isolates neutralized by 20, 10 and 5AU for each different cut-off or analysis method used.
Cut-off Number of VN results 20AU 10AU 5AU
AUs based on individual experiment FCV-F9 homologous control 98 50 36 27
AUs for those isolates where the titre for the internal F9 control was within 2-fold of
mean F9 titre across all experiments
25 32 20 0
6 M.M. Afonso et al. / Vaccine xxx (2017) xxx–xxxpopulation, a cross-sectional survey sampling cats from randomly
recruited veterinary practices was undertaken. This approach also
provided an opportunity to assess the epidemiology and molecular
epidemiology of FCV infection.
Consistent with previous studies, cats in multi-cat households,
those with CGS, and younger cats, were more likely to shed FCV
[26,36]. Chronic gingivostomatitis affects 0.7% of the population
[37], with most affected cats testing FCV positive [29,36]. Previous
studies have shown that FCV prevalence increases from around
10% in single-cat households to over 50% in some larger colonies
[4,38]. These large colonies are believed to drive antigenic diversity
as strain variants evolve under positive selection within a variable
population immunity [4,39]. In addition, neutered cats were less
likely to test positive for FCV regardless of age. This suggests beha-
vioural changes associated with neutering, such as becoming less
territorial, may lower FCV risk as has also been shown for feline
immunodeficiency virus [40,41]. We also found that cats in some
countries (the Netherlands) had a higher prevalence of FCV infec-
tion than those from others (France, Italy, UK). Whether this repre-
sents true population differences, or the relatively small sample
sizes in some countries will need to be assessed further.
The phylogenetic analysis is broadly in agreement with previ-
ous national and international studies [9–11,14], highlighting a
radial phylogeny with little evidence for sub-species clustering
except viruses sharing immediate temporal or spatial links. As pre-
viously [4,11,42], FCV-F9 variants were found in this population,
five from the UK and two from Sweden, of which four had been
vaccinated with FCV-F9 attenuated vaccines <25 days prior to sam-
pling, one was un-vaccinated for at least three years, and one a res-
cue cat that was presumed unvaccinated. The only time such
vaccine-derived viruses are not observed is when recently vacci-
nated cats are excluded from the sampled population [10]. OurPlease cite this article in press as: Afonso MM et al. A multi-national European
cine cross-reactivity. Vaccine (2017), http://dx.doi.org/10.1016/j.vaccine.2017.0findings are consistent with experimental studies showing occa-
sional shedding of vaccine virus following live-FCV vaccination
[20,43]. Looking at the diversity within this FCV-F9 clade, six of
the seven strains were <3.6% distant from the FCV-F9 published
sequence, suggesting they had not been replicating for long in
the cat, consistent with recent vaccination history of most of these
cats. In contrast, a Swedish isolate from a vaccinated cat (unknown
strains), was 16.9% different to FCV-F9, possibly representing a rare
persisting and evolving strain of FCV-F9 or an unrelated strain.
Taken together, this confirms that whilst live vaccine viruses are
occasionally shed following vaccination, they only seem to have
a limited potential to persist in the general cat population.
The balance between antibody- and cell-mediated immunity in
FCV protection is somewhat uncertain. Some cats exposed to pre-
vious FCV antigens show protection to heterologous challenge,
even when there are no demonstrable in vitro antibodies to the
new challenge [29], suggesting that other factors including cellular
immunity contribute to protection. That said, it is still believed that
there is sufficient correlation between antibody levels and protec-
tion, for in vitro virus neutralisation tests to remain the accepted
method of assessing cross-reactivity [16,24–26]. Therefore, we
have used a pool of plasma raised to 10 doses of FCV F9 vaccine,
and demonstrated neutralising activity to the majority of this
cross-sectional European panel of contemporary FCV isolates.
These results are broadly similar to those observed in a similar
cross-sectional study of FCV-F9 strain diversity in the UK in 2001
[26]. When results are expressed as antibody units to try and con-
trol for variations in sera production (infection vs vaccination over-
dose), and the between-cat variation, the percentage of isolates
neutralized by 20, 10 and 5 AUs was similar to, or higher than, that
from the earlier study in 2001 [26]. When taken together, this sug-
gests antisera against FCV-F9 remains broadly cross-reactivecross-sectional study of feline calicivirus epidemiology, diversity and vac-
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with our observation that, despite its age, FCV-F9 remains an inte-
gral part of this contemporary phylogeny, and suggesting that FCV
may not evolve in a linear (‘‘clock-like”) fashion, such as is typical
for other rapidly evolving viruses [44,45].
These conclusions are in contrast with other studies suggesting
the levels of FCV-F9 cross-reactivity have reduced over time [23–
25]. However, two important methodological differences between
studies make direct comparisons impossible. Firstly, previous stud-
ies used isolates collected by convenience from diagnostic labora-
tories; these should not be considered representative of those in
the general population [24]. Secondly, previous studies have used
infection rather than vaccination to produce antisera of sufficient
titre for testing; differences in viral replication and antigen presen-
tation between virus replicating locally in target tissues of the
upper respiratory tract as opposed to the subcutaneous tissues at
the site of vaccination, are likely to impact in albeit unknownways,
on the nature of the ensuing immune response, and this impact is
likely to be greatest for viral antigens from inactivated vaccines.
Here for the first time we used subcutaneous vaccination (albeit
at 10 release dose), of a live vaccine, using a cross-sectional sam-
ple of contemporary FCV isolates to maximise the generalizability
of our results. Clearly these in vitro results cannot be used to sug-
gest the rate of cross-protection in the field. To facilitate better
comparison between these studies in the future, we recommend
the development of an internationally agreed study protocol as
exists for some other viral vaccines.Conflict of interest
This project was funded by MSD Animal Health who market a
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